Review of an established UK home phototherapy service 1998–2011: improving access to a cost-effective treatment for chronic skin disease

• Published in: Public health (London) 2014-04, Vol.128 (4), p.317-324
• Main Authors: Cameron, H, Yule, S, Dawe, R.S, Ibbotson, S.H, Moseley, H, Ferguson, J
• Format: Article
• Language: English
• Subjects: Ambulatory Care - economics; Chronic Disease; Cost-Benefit Analysis; Databases, Factual; Equality of access; Health Services Accessibility - economics; Health Services Research; Home Care Services - economics; Home phototherapy; Humans; Infectious Disease; Internal Medicine; Narrowband ultraviolet B; Phototherapy - economics; Psoriasis - economics; Psoriasis - therapy; Surveys and Questionnaires; TL-01; United Kingdom
• ISSN: 0033-3506; 1476-5616
• DOI: 10.1016/j.puhe.2014.01.011

Abstract Objectives To review the Tayside home phototherapy service, including numbers of patients treated, diagnoses and outcomes, side-effects and safety, cost-effectiveness and absolute costs. To consider why home or outpatient phototherapy is not available to all patients who might benefit and how this could be addressed. Study design Observational and cost analysis. Methods Analysis of the Tayside home phototherapy database 1998 and 2011, home phototherapy patient questionnaires, outcome data, costs and a comparison with outpatient phototherapy. Review of literature and current national guidelines for phototherapy, traditional systemic and biologic therapies for psoriasis. Results 298 courses of home narrowband UVB (NB-UVB) phototherapy were undertaken by 212 patients between 1998 and 2011, five courses in 1998 increasing to 36 in 2011. The main diagnoses treated were psoriasis (72%), atopic dermatitis (8%), and desensitization of photodermatosis (7%). For psoriasis, 74.5% achieved clearance or minimal residual activity in a median of 30 exposures (range 10–60). The estimated costs to the hospital ranged from £229 to £314 per course (£307 to £422 per effective course for psoriasis), compared with £114 for out-patient therapy (£149 per effective course for psoriasis). The total cost to society (hospital and patient costs) is around £410 per course, compared to an estimated £550 for outpatient therapy for this group of patients. Treatment was well tolerated, erythema rates were similar to outpatient therapy, there were no complaints and the vast majority would choose home over outpatient phototherapy if required in the future. Conclusions Hospital supervised home phototherapy appears as safe and effective as outpatient therapy and provides equality of access for patients who cannot attend for outpatient therapy. These patients may otherwise be inadequately treated or given more costly and higher risk systemic therapies, particularly for psoriasis. Commissioners and clinicians involved in dermatology services should provide accessible phototherapy for all patients who might benefit, utilizing home phototherapy where outpatient access is not possible.